Business context and reporting period
OmniAb, Inc. is a biotechnology company that licenses antibody-discovery technologies and earns revenue from technology access, research services, partner milestones, and royalties. This unaudited Form 10-Q covers the three months ended March 31, 2024, compared with the same period in 2023.
At quarter-end, OmniAb reported 80 active partners and 327 active programs, including 27 partner programs in clinical development, one under regulatory review, and three approved products.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Total revenue | $3.8 million | $16.9 million |
| Operating expenses | $26.4 million | $25.4 million |
| Loss from operations | $22.6 million | $8.5 million |
| Net loss | $19.0 million | $6.1 million |
| Basic and diluted loss per share | $0.19 | $0.06 |
| Net cash from (used in) operating activities | $(17.0) million | $27.7 million |
Revenue comprised $0.7 million in license and milestone revenue, $2.8 million in service revenue, and $0.3 million in royalties. The filing does not present a gross profit or gross margin measure.
At March 31, cash and cash equivalents were $19.1 million and short-term investments were $49.9 million, for combined cash and investments of $69.0 million. Current assets were $76.7 million and current liabilities were $17.5 million. Total liabilities were $51.2 million; the balance sheet lists operating lease and contingent liabilities but no separate borrowings or debt balance. The company reported $24.9 million in present-value operating lease liabilities.
Investing activities provided $19.9 million, mainly from investment maturities; financing activities used $0.2 million. Cash, cash equivalents, and restricted cash increased $2.7 million during the quarter. Management said existing cash, investments, and expected operating cash generation should support operations for at least the next 12 months.
Material changes versus the prior comparable period
- Revenue decreased 78% year over year. License and milestone revenue fell 94%, primarily because Q1 2023 included a $10 million milestone associated with the first EU commercial sale of teclistamab. Service revenue declined 30%, reflecting completion of work on certain ion-channel programs. Royalty revenue was broadly unchanged.
- Operating expenses increased 4%; research and development expense rose 6%, primarily due to personnel costs.
- Net loss widened by $12.9 million. Operating cash flow shifted from $27.7 million provided to $17.0 million used; the prior-year result benefited substantially from working-capital movements, including accounts receivable collections.
- Active partners increased from 77 to 80 and active programs from 325 to 327. Active clinical programs and approved products decreased from 32 to 31; approved products remained at three.
Outlook, management commentary, risks, and unusual items
- Management expects continued losses as it invests in research and development, partner development, and public-company operations. It may need additional capital if cash flows or demand are insufficient; financing may not be available on acceptable terms.
- The company expects milestones to be an important nearer-term revenue driver and royalties to be a longer-term source, but timing and achievement are uncertain. OmniAb does not control partners’ clinical development, regulatory decisions, or commercialization, and partners may terminate agreements subject to their terms.
- Management noted that warrants were out of the money at the report date: their $11.50 exercise price exceeded the common-stock trading price. The potential $218.6 million of proceeds assumes all warrants are exercised for cash and is not assured.
- Q1 income tax benefit was $2.6 million; the effective tax rate was 12.1%, affected by tax credits, stock-award tax effects, and valuation allowances on deferred tax assets.
- Contingent liabilities totaled $4.1 million at quarter-end, primarily associated with the Icagen acquisition. Management said pending legal matters were not expected to materially affect the financial statements, while noting litigation outcomes remain uncertain.
- No material changes to previously disclosed risk factors or market risks were reported. Management concluded disclosure controls and procedures were effective at the reasonable-assurance level, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether new partner access, service work, and milestone events can offset the comparison against the prior-year $10 million milestone and sustain revenue growth.
- Quarterly operating cash burn and the assumptions behind management’s stated cash runway of at least 12 months.
- Progress, attrition, and commercialization of the 327 active programs, including the 27 clinical programs and three approved products; revenue depends materially on partner decisions and execution.
- Potential dilution from outstanding options, restricted stock units, earnout shares, and warrants. The filing lists 61.1 million anti-dilutive or contingently issuable share equivalents, excluded from diluted loss per share.
- Changes in contingent liabilities, lease commitments, and the realizability of deferred tax assets and associated valuation allowances.